Market Access Indication-specific pricing in England: Business as usual? Leela Barham highlights data that shows that indication-specific pricing has been used in England for at least four years and over 60 times.
Market Access Missing metrics on the UK’s VPAG It's hard to take stock of what’s happening operationally with the UK's main pricing scheme, VPAG, given the absence of reporting by the DHSC.
Market Access FT Summit: How Is U.S. Policy Reshaping the UK and EU Pharma... For the Financial Times (FT) Global Pharma & Biotech Summit in London 2025, pharmaphorum is providing coverage courtesy of NAVLIN Daily.
Views & Analysis 'Free' pricing in the UK: the influence of NICE and NHS Engl... UK drug pricing: just how free is free pricing, these days?
News NHS staff 'feel unprepared for digital transformation' A survey of NHS workers has found that almost two-thirds feel they are unprepared for the digital transformation objectives of the 10-Year Plan.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.